The abstract was selected as late-breaking oral presentation at EULAR. BTK inhibitor orelabrutinib was generally well tolerated in patients with SLE.

Updates in AxSpA from EULAR 2025 include 3-year data for bimekizumab, definition of difficult-to-manage subgroups, effectiveness of a digital therapeutic app, and a potential cell-therapy approach.

The School of Infection & Immunity's Musculoskeletal Research Team has been named a EULAR Centre of Excellence in Rheumatology Research at the recent congress held in Barcelona. The renewed status, ...

The versatility of ion pairing is further illustrated by α-cyano carbanions in Pd-catalyzed decarboxylative allylic alkylations and is extended to a cooperative catalytic system, where DMAP-generated ...

Several European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of people with specific I-RMDs have highlighted the importance of non-pharmacological ...

From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in rheumatology care.

According to a EULAR press release, the data “suggest the potential for CAR T-cell therapy and other B-cell depleting therapies to reset the immune system in multiple RMD, allowing patients to ...